In the previous funding period, based on the hypothesis that maintenance of telomere function is critical to MM cell survival, we investigated the mechanisms maintaining telomere function in MM and evaluated inhibitors of telomerase/telomeres as novel therapeutics. We have shown that telomerase activity is increased, while telomere length is shorter, in MM cells and cell lines compared to normal plasma cells, providing a critical therapeutic index for using telomere maintenance mechanism-directed novel therapeutics. We have further evaluated the mechanisms regulating telomerase activity in MM. Specifically, we have identified that the important MM survival signals are also mechanisms maintaining telomerase activity. We have demonstrated that IL-6 and IGF-1, which induce MM cell proliferation and survival, also increase telomerase activity;these cytokines augment telomerase activity through NFkB-mediated upregulation of both hTERT mRNA and protein expression;as well as through Akt-mediated hTERT phosphorylation and activation. We have also gone on to show that hsp90 complexes with and modulates telomerase activity; conversely, inhibition of hsp90 by 17-AAG leads to inhibition of telomerase activity. Finally, we have evaluated the effects of various inhibitors of telomerase in MM and identified efficacy of GRN163L, an antisense lipidated oligonucleotide hTERT inhibitor, both in vitro as well as in vivo in a murine model of human MM. In this renewal application, we are initiating a phase I study of GRN163L in relapsed and relapsed refractory MM, we will evaluate the clinical and molecular effects of GRN163L in myeloma;as well as identify agents that are synergistic with telomerase inhibition in preclinical in vitro and in vivo models. The molecular correlates of response versus resistance identified in the single agent clinical study, coupled with preclinical identification of combinations with synergistic anti-MM activity, will provide the framework for combination clinical trials. To this end, the following aims will be pursued:
Specific Aim 1 : To investigate safety, efficacy, and molecular correlates of telomerase-targeting GRN163L therapy in patients with relapsed or refractory MM;
Specific Aim 2 : To define rationally-based combinations of telomerase inhibitor and novel agents which mediate synergistic MM cytotoxicity in vitro;
and Specific Aim 3 : To define the in vivo efficacy of telomerase inhibitor combination therapies in murine models of human MM for translation to derived clinical studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA100707-10
Application #
8382441
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2013-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
10
Fiscal Year
2012
Total Cost
$216,113
Indirect Cost
$59,842
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Zhang, L; Tai, Y-T; Ho, M et al. (2017) Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu. Blood Cancer J 7:e547
Jain, Salvia; Washington, Abigail; Leaf, Rebecca Karp et al. (2017) Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Mol Cancer Ther 16:2304-2314
Gullà, A; Hideshima, T; Bianchi, G et al. (2017) Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. Leukemia :
Harada, T; Ohguchi, H; Grondin, Y et al. (2017) HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications. Leukemia 31:2670-2677
Cholujova, Danka; Bujnakova, Zdenka; Dutkova, Erika et al. (2017) Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. Br J Haematol 179:756-771
Bouillez, A; Rajabi, H; Jin, C et al. (2017) MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene 36:4037-4046
Das, Deepika Sharma; Das, Abhishek; Ray, Arghya et al. (2017) Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clin Cancer Res 23:4280-4289
Tagde, Ashujit; Markert, Tahireh; Rajabi, Hasan et al. (2017) Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma. Oncotarget 8:69237-69249
Ray, A; Das, D S; Song, Y et al. (2017) Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma. Leukemia :
Song, Y; Li, S; Ray, A et al. (2017) Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Oncogene 36:5631-5638

Showing the most recent 10 out of 388 publications